HomeNewsImmunosuppressants

Immunosuppressants

Jump to

Concord Biotech: Strong grip on fermentation APIs stays

Though valuations are at a premium, the company has strong earnings prospects ahead
Biocon Q3 PAT seen up 19%, revenue may grow 20%: Poll

Core sales growth of 20 percent will be led by biopharma, India formulations and CRAMS business, analysts say, adding Biopharma will be lead by immunosuppressants (Serolimus) and insulin in emerging markets.
Morgan Stanley raises Biocon to 'overweight', stk gains 2%

Morgan Stanley said improving base business fundamentals should help Biocon deliver mid-teens growth, and there were other growth platforms in the pipeline like human insulin, monoclonocal antibodies and immuno-suppressants.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Immunosuppressants

Concord Biotech: Strong grip on fermentation APIs stays

Biocon Q3 PAT seen up 19%, revenue may grow 20%: Poll

Morgan Stanley raises Biocon to 'overweight', stk gains 2%